Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Ultragenyx Pharmaceutical has raised $400.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in November 2025.
Ultragenyx Pharmaceutical's investors include Takeda, HealthCap, TPG Growth, F-Prime, Adage Capital Management.
Ultragenyx Pharmaceutical is headquartered in Novato, United States.
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Ultragenyx Pharmaceutical is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ultragenyx Pharmaceutical — Funding & Investors." VCBacked, November 4, 2025, https://www.vcbacked.co/company/ultragenyx-pharmaceutical. Accessed August 15, 2026.
VCBacked. (2025). Ultragenyx Pharmaceutical — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/ultragenyx-pharmaceutical
{{cite web |title=Ultragenyx Pharmaceutical — Funding & Investors |url=https://www.vcbacked.co/company/ultragenyx-pharmaceutical |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated